Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
One Percent Rule Checklist For Safer Forex Trading Risk 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
BOSTON, April 18, 2017 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced that it will host a conference call and webcast on Thursday, May 4, 2017 at 8:00 a.m. ET to discuss its first quarter 2017 financial results and provide corporate updates.
To participate in the conference call, please dial 1-888-396-2320 (U.S.), 1-774-264-7560 (international) and refer to conference ID: 8810002. The call will be webcast live with slides and accessible through the Investors section of the company’s website at www.keryx.com for a period of 15 days after the call.
Keryx Biopharmaceuticals will announce its financial results for this period in a press release to be issued prior to the call.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts is a commercial stage company focused on bringing innovative medicines to people with renal disease. Keryx developed and commercializes Auryxia® (ferric citrate) in the U.S. Ferric citrate is marketed as Riona® by Keryx’s Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex). Keryx has programs underway to leverage its development and commercial infrastructure, including potentially expanding the indication of Auryxia and in-licensing medicines for renal disease. For more information about Keryx, please visit www.keryx.com.
Keryx Biopharmaceuticals Contact: Lora Pike Senior Director, Investor Relations & Corporate Communications T: 617.466.3511 [email protected]
